Semaglutide Injections for Weight Loss: What You're Deciding

What semaglutide injections actually do inside your body

The decision to start any treatment usually begins with understanding the mechanism — and with semaglutide injections it is worth being precise, because the name covers several medicines with different licences.

Semaglutide binds to GLP-1 receptors found throughout the body: in the gut, the pancreas and, critically, the brain's appetite centres. When the receptor is activated, signals of fullness arrive faster, hunger between meals falls and gastric emptying slows so food stays with you longer. The result, for most people, is a meaningful reduction in calorie intake without the conscious effort of restriction. NHS guidance on semaglutide describes the mechanism clearly and is worth reading before starting.

It is a single-receptor agonist, working only on GLP-1 pathways. Tirzepatide (Mounjaro) also activates GIP receptors, which is one reason the two medicines sit differently in head-to-head trial data — but that is a separate treatment decision explored elsewhere on this site.

What semaglutide injections do not do is act quickly. The titration schedule exists because the therapeutic effect builds gradually; the starter dose settles your system before the prescriber moves you up. Patience at this stage matters.

How the injection itself works in practice

A question our prescribers hear most weeks is whether injecting once a week at home is really manageable. For almost everyone who tries it, the answer is yes.

Wegovy arrives as a pre-filled, pre-set pen. You do not draw up a dose, you do not see a needle being inserted, and the mechanism is designed so the injection is largely hands-off. The pen is injected into the fatty tissue just below the skin (abdomen, thigh or upper arm) and you rotate sites between doses.

The practicalities worth knowing: the pen is stored in the fridge (2–8°C) and removed about 30 minutes before use to reach room temperature. You should use a fresh needle for each dose, and used pens and needles go into a sharps container rather than the household bin. For a full step-by-step walkthrough of technique, our guide to taking semaglutide injections covers the process in detail, including what to do if you forget a dose, though your prescriber and the Patient Information Leaflet are always the authoritative source on timing questions.

The injected dose enters the bloodstream slowly; peak levels are reached around 24–48 hours after injection and the medicine remains active across the full week. That steady-state profile is why missing a dose by a day or two matters less than with a daily medicine, though consistency week to week is still the goal.

Side effects worth weighing before you decide

The side-effect profile of semaglutide injections is dominated by the gut. Nausea is the most commonly reported effect, followed by loose stools or constipation, reflux, burping and occasional vomiting. For the majority of people these settle within a few weeks of each dose step, rather than persisting throughout treatment. The graduated titration schedule exists specifically to give the body time to adjust.

A smaller proportion of people experience headache, fatigue or dizziness, particularly in the early weeks. Injection-site reactions (mild redness or itching) are possible but usually brief.

More serious but less common: the MHRA issued a Drug Safety Update in January 2026 flagging acute pancreatitis as a known, infrequent risk across GLP-1 medicines. Severe stomach pain that spreads to the back, with or without vomiting, warrants urgent medical attention. Gallbladder problems, dehydration from prolonged vomiting, and in rare cases allergic reactions are also documented. The full safety profile (including contraindications) is in the medicine's Patient Information Leaflet and on the NHS semaglutide page.

Semaglutide injections are not recommended during pregnancy, while breastfeeding, or for anyone trying to conceive. They are not licensed for use under 18. Anyone with a history of medullary thyroid carcinoma or MEN2 syndrome should discuss this with a clinician before considering treatment. If you take an oral contraceptive pill and start tirzepatide specifically, there are additional considerations that a prescriber will cover at consultation.

Who is eligible and how to access semaglutide injections in the UK

The licensed eligibility for Wegovy (the weight-management form of semaglutide injection) is adults with a BMI of 30 or above, or a BMI of 27–29.9 alongside at least one weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. BMI alone does not determine suitability; a prescriber assesses the full clinical picture.

NICE recommends semaglutide for weight management (TA875) within specialist NHS services, for a maximum of two years, for people with a BMI of 35 or above and at least one comorbidity, with ethnic-background thresholds typically 2.5 kg/m² lower. NHS waiting lists for specialist services can be long, and not everyone meets the current NHS criteria. A private prescription route, through a regulated pharmacy you can verify on the GPhC register, is the alternative for those who do not want to wait or do not meet NHS thresholds.

It is also worth knowing that Ozempic, the other semaglutide injection, is licensed for type 2 diabetes rather than weight management, the two products are not interchangeable for this purpose. And if you are curious whether there is an alternative to injecting at all, oral semaglutide is now also available in the UK, approved by the MHRA in June 2026.

If you would like to explore whether semaglutide injections suit your situation, speak to our prescribers through a free consultation, reviewed the same day by a GPhC-registered Independent Prescriber, with no waiting list.